KZIA (Kazia Therapeutics) Institutional Ownership : 6.45% (As of Dec. 15, 2024)

View and export this data going back to 1999. Start your Free Trial

What is Kazia Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kazia Therapeutics's institutional ownership is 6.45%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kazia Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kazia Therapeutics's Float Percentage Of Total Shares Outstanding is 99.69%.

Kazia Therapeutics Institutional Ownership Historical Data

The historical data trend for Kazia Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Institutional Ownership Chart

Kazia Therapeutics Historical Data

The historical data trend for Kazia Therapeutics can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Institutional Ownership	0.02	0.02	0.02	0.02	0.01	0.04	0.04	0.04	0.03	0.03

Kazia Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Kazia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204